Vir Bio trims staff and pipeline to focus on Sanofi-licensed programmes
The company has fired 25% of staff and discontinued pipeline programs to funnel funds into developing candidates licensed from Sanofi.
05 August 2024
05 August 2024
The company has fired 25% of staff and discontinued pipeline programs to funnel funds into developing candidates licensed from Sanofi.
The MAGE-A4-targeted genetically modified T cell therapy is indicated for the treatment of synovial sarcoma.
Alemtuzumab, under the brand name Campath, was pulled from the leukaemia market by Sanofi in 2012.
Casgevy is one of seven gene therapies and gene-modified cell therapies to have launched on the US market with an average price per unit that is above $1m.
Rejuvenate and SAS will create a tool to simplify the drug development process, used to repurpose drugs for age-related diseases.
A decision on regulatory approval for the ticagrelor reversal treatment is expected in Q1 2025.
Amylyx reported positive interim analysis results from its Phase II HELIOS clinical trial of AMX0035.
The NIAID funding will facilitate IND-enabling activities and a subsequent Phase I trial of the vaccine in humans.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.